Trial Profile

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aceclidine (Primary) ; Aceclidine/brimonidine (Primary)
Indications Presbyopia
Focus Registrational; Therapeutic Use
Sponsors Corxel Pharmaceuticals

Most Recent Events

03 Mar 2025 Status changed from active, no longer recruiting to completed.
06 Nov 2024 Topline results presented in the LENZ Therapeutics Media Release.
28 Oct 2024 Primary endpoint (Best-corrected distance visual acuity (BCDVA) at 40 cm) has been met as per results presented CORXEL in the Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com